• The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.1
  • This minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods.
  • By providing deeper insight into underlying neuroinflammatory activity, Elecsys NfL has the potential to enable effective MS monitoring and earlier clinical intervention. 2, 3